boehringer glp-1 advances #first #triple #agonist #bi3034701 #obesity #pipeline #glp #gip #npy2 #glucagon #glp #boehringeringelheim #obesity #glp1 #gip #npy2 #cardiometabolic #phase2 #clinicaltrials #drugdevelopment… Boehringer's GLP-1 dual agonist survodutide

Resolves quickly with proper fluid intake but requires ongoing vigilance Serious But Less Common Side Effects The MHRA highlights several serious but less common risks that patients should know about 1 : Gallbladder problems: Including gallstones Pancreatitis: Inflammation of the pancreas, which can require hospitalization Allergic reactions: Can include swelling, rash, and trouble breathing Low blood sugar: Can happen even in non-diabetic patients using GLP-1s for weight loss Hair loss: Some patients report temporary thinning of hair Warnings About Misuse Healthcare professionals are concerned about people using GLP-1 medications inappropriately just for cosmetic weight loss

(2025) The effect of GLP-1 agonist on idiopathic intracranial hypertension: a systematic review and meta-analysis

Take Amy Saunders, 45, of Stafford, Virginia, who found herself putting on weight while trying to quit smoking

Sitagliptin was granted FDA approval on 16 October 2006 (National Center for Biotechnology Information, 2023f)

No significant differences in secondary outcomes were observed post-weighting, and all results were consistent across multiple sensitivity analyses

Fusar-Poli, P